Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease

Martina Sattlecker, Mizanur Khondoker, Petroula Proitsi, Stephen Williams, Hilkka Soininen, Iwona Kloszewska, Patrizia Mecocci, Magda Tsolaki, Bruno Vellas, Simon Lovestone, Richard J. B. Dobson, AddNeuroMed Consortium

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

Biomarkers of Alzheimer's disease (AD) progression are needed to support the development of urgently needed disease modifying drugs. We employed a SOMAscan assay for quantifying 1,001 proteins in blood samples from 90 AD subjects, 37 stable mild cognitive impaired (MCI) subjects, 39 MCI subjects converting to AD within a year and 69 controls at baseline and one year follow up. We used linear mixed effects models to identify proteins changing significantly over one year with the rate of cognitive decline, which was quantified as the reduction in Mini Mental State Examination (MMSE) scores. Additionally, we investigated proteins changing differently across disease groups and during the conversion from MCI to AD. We found that levels of proteins belonging to the complement cascade increase significantly in fast declining AD patients. Longitudinal changes in the complement cascade might be a surrogate biomarker for disease progression. We also found that members of the cytokine-cytokine receptor interaction pathway change during AD when compared to healthy aging subjects.

Original languageEnglish
Pages (from-to)1105-1114
Number of pages10
JournalJournal of Alzheimer's Disease
Volume49
Issue number4
DOIs
Publication statusPublished - 2016

Keywords

  • Alzheimer's disease
  • cognitive decline
  • complement cascade
  • cytokine-cytokine receptor interaction
  • plasma proteins

Cite this